



Life Settlement Assets PLC – Ordinary Share A

Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Estimated Performance



Commentary

outcomes.

Investment Terms

1.5% Management Fee

Estimated NAV (USD) 108 771 871

NAV/Share 2.2594 The Share Class is reporting a performance of -0.22% for the month of June. Six HIV maturities were registered, contributing a total Death Benefit of \$0.5M; one maturity for a total face value of \$1.1M was registered in the non-HIV segment this month. In addition, the company has started buying back shares on the stock market.

The pandemic significantly reduced life expectancy gains in America, which now

has the highest per capita health spending globally at over \$12,500. Despite this, the U.S. has the lowest life expectancy among wealthy countries. A study comparing 12 developed nations reveals that while the average health expenditure per capita is \$6,700 with a life expectancy of 82.2 years, Americans spend nearly double for a life expectancy of just 77.5 years. Notably, the U.K. has the lowest healthcare costs among its peers, partly due to its National

Health Service, while Japan boasts one of the highest life expectancies at 84


years with relatively low health spending of \$5,300 per capita. These disparities highlight the influence of various socioeconomic factors on healthcare costs and

Number Of Policies		Net Death Benefits (USD)	Matured Policies YTD		Maturities YTD (USD)
3 879		416 914 017	61	61	
Trust Investment Manager	Acheron Capital Ltd.		Company Secretary	ISCA Administration Services Limited	
Administrator	Comp	agnie Européenne de Révision	ISIN Ticker	GB00BF1Q4B05 LSAA	
Auditor	BDO U	IK LLP	Info	life@ache +44 207 2	eroncapital.com 58 5990


June 2024










Distribution By Gender




Distribution by Insurance Company







Maturities Since Inception




(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.
(2)Distribution by issue dates reflects the time since the life insurance policy was issued.
Source of Data: Acheron Capital Ltd unless otherwise stated.

June 2024








Maturities June 2024

Number of policies matured in June 2024	7
Corresponding number of insured	6
Total death benefit in June 2024 (US\$)	1 566 016
Valuation of Matured policies (US\$)	536 437



Premiums Situation (US\$)⁽¹⁾

Servicers Premiums Projection for the next 12 months	\$ 14.0M
Mortality Adjusted Premiums Projection for the next 12 months	\$ 13.5M
Estimated COI Net of Mortality for the next 12 months	\$ 13.0M

Top 10 Coverage

		Total Face	Age	
Insured	Face (millions)	(millions)	(ALB)	Expiration Age*
1	7.2	7.2	99	110
2	2.0/1.0/1.0/0.9/0.3	5.2	96	100/100/100/100/100
3	3.0	3.0	94	100
4	3.0	3.0	68	90
5	1.5/1.0/0.3	2.8	93	100/100/100
6	2.8	2.8	93	100
7	2.0	2.0	89	110
8	2.0	2.0	103	120
9	1.0/0.5	1.5	67	100/100
10	0.7/0.4/0.3	1.4	97	100/100/100

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus June only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they June not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.